Table 1 Baseline characteristics of the study participants
From: Association between peripheral lymphocyte count and the mortality risk of COVID-19 inpatients
Variables | Outcomes of Patients | P value | |
|---|---|---|---|
Survival (n = 113) | Non-survival (n = 21) | ||
Male, n (%) | 47 (41.59) | 13 (61.90) | 0.086 |
Age (year) | 56 ± 14 | 65 ± 10 | 0.004 |
Smoking, n (%) | 9 (8.0) | 1 (4.8) | 0.608 |
Arterial oxygen saturation, (%) | 97.1 ± 6.6 | 83.5 ± 14.4 | < 0.001 |
COPD, n (%) | 4 (3.6) | 1 (4.8) | 0.583 |
Hypertension, n (%) | 34 (30.1) | 3 (14.3) | 0.625 |
Diabetes mellitus, n (%) | 8 (7.1) | 4 (19.0) | 0.078 |
Heart disease, n (%) | 12 (10.6) | 3 (14.3) | 0.625 |
Chronic kidney disease, n (%) | 2 (1.8) | 0 (0.0) | 1.000 |
Stroke, n (%) | 2 (1.8) | 3 (14.3) | 0.027 |
Fever (°C), n (%) | 0.509 | ||
< 37.3 | 11 (9.7) | 2 (9.5) | |
37.3–38.0 | 31 (27.4) | 6 (28.6) | |
38.1–39.0 | 53 (46.9) | 7 (33.3) | |
> 39.0 | 18 (15.9) | 6 (28.6) | |
Cough n (%) | 88 (77.9) | 17 (81.0) | 0.753 |
Sputum production, n (%) | 32 (28.3) | 5 (23.8) | 0.671 |
Dyspnea, n (%) | 64 (56.6) | 16 (80.0) | 0.049 |
Haemoptysis, n (%) | 2 (1.8) | 2 (10.5) | 0.100 |
Laboratory tests | |||
WBC (× 109/L) | 5.07 ± 1.99 | 8.14 ± 4.77 | 0.003 |
Lymphocyte count (× 109/L) | 1.16 ± 0.53 | 0.69 ± 0.52 | < 0.001 |
Platelets (× 109/L) | 212 ± 96 | 169 ± 103 | 0.041 |
C-reactive protein (mg/L) | 17.9 (6.2–43.2) | 78.0 (42.9–119.4) | < 0.001 |
PT (S) | 11.7 ± 4.2 | 14.0 ± 5.1 | 0.026 |
D-dimer (mg/L) | 0.5 (0.3–1.1) | 1.6 (0.3–8.5) | 0.027 |
Albumin (g/L) | 36.8 ± 6.7 | 35.7 ± 9.5 | 0.491 |
Uric acid (mmol/L) | 259 ± 89 | 311 ± 117 | 0.024 |
LDH (IU/L) | 220 (178–285) | 337 (241–581) | 0.002 |
CK (IU/L) | 101.0 (60.1–196.0) | 199.0 (92.0–453.3) | 0.006 |
CK-MB (IU/L) | 9.0 (5.2–12.7) | 17.4 (12.0–34.7) | < 0.001 |
Lesions on chest CT scan, n (%) | 0.574 | ||
Unilateral lung | 12 (10.81) | 1 (6.25) | |
Bilateral lungs | 99 (89.19) | 15 (93.75) | |